In this article
According to the CALGB 89903 study published in the Journal of Clinical Oncology, patients with stage III colon cancer who eat at least 2 servings of nuts per week have higher disease-free survival (DFS) and overall survival (OS). The association between total nut intake and improved outcomes is consistent among other known or suspected risk factors for cancer recurrence and death.
Dr. Charles S. Fuchs of the Yale Cancer Center and colleagues wrote: "This prospective study of patients with stage III colon cancer shows that a diet with increased nut consumption is associated with a significant reduction in cancer recurrence and mortality. Although we observed the results of observational studies and cannot determine causality, the results further support diet and lifestyle as modifiable risk factors for patients with colon cancer."
This study conducted a 6.5-year follow-up survey of 826 colon cancer patients treated with surgery and chemotherapy. The results showed that people who consumed at least two ounces of nuts per week had a 42% increase in disease-free survival and a 57% increase in overall survival. Further analysis of the cohort confirmed that the disease-free survival of participants who consumed nuts significantly increased. The nuts included in this benefit were tree nuts such as almonds, walnuts, hazelnuts, and cashews. Peanuts, which are technically a legume rather than a tree nut, were not associated with the same benefit.
The findings emphasize the importance of diet and lifestyle factors in the survival of colon cancer patients. The researchers noted that these results are consistent with other observational studies showing that a range of healthy behaviors — including increasing physical activity, maintaining a healthy weight, and reducing the intake of sugar and sugary drinks — can improve survival rates in colon cancer patients.
In addition, the researchers highlighted that the study underscores not only the connection to colon cancer but also the biological mechanisms shared with certain chronic diseases, such as type 2 diabetes, which is known to worsen colon cancer outcomes. While the observational nature of the study means causality cannot be definitively established, the strength and consistency of the findings across multiple risk factors make a compelling case for incorporating regular tree nut consumption as part of a broader cancer-protective lifestyle for patients with colon cancer.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.